This is a cutting-edge technology that has a truly international potential since it can compete with the most advanced clot-buster drug currently available (TPA, tissue plasminogen activator), The technology will be sufficiently scaled-up in-house so that after transfer to a commercial partner it has a minimum take-off period.
Accessibility Controls